MoonLake Immunotherapeutics MLTX

MLTX Company Overview

MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing immunology therapies for inflammatory diseases. The company’s lead asset is sonelokimab, a tri-specific Nanobody designed to target interleukin-17A and interleukin-17F pathways associated with chronic inflammatory disorders. MoonLake operates within the biotechnology and biopharmaceutical industries, with a primary emphasis on immunology, dermatology, rheumatology, and related inflammatory conditions.

The company’s core value proposition is centered on the potential differentiation of its Nanobody platform, which is designed to offer tissue penetration, molecular specificity, and dosing flexibility compared with conventional monoclonal antibody therapies. MoonLake has concentrated its development efforts on diseases such as hidradenitis suppurativa, psoriatic arthritis, and other IL-17-mediated conditions. The company evolved from a privately held biotechnology venture into a publicly traded entity through a business combination with Helix Acquisition Corp., after which it began trading on Nasdaq under the ticker MLTX.